Cancer Genetic Counseling & Testing | NYU Langone Health
Genetic counselors at Perlmutter Cancer Center’s High-Risk Cancer Genetics Program assess risk and provide genetic counseling and testing.
Cancer Genetics Team | NYU Langone Health
The High-Risk Cancer Genetics Program team at NYU Langone’s Perlmutter Cancer Center includes genetic counselors who specialize in cancer.
Cancer Navigator Program | NYU Langone Health
The Cancer Navigator Program at Perlmutter Cancer Center at NYU Langone Hospital—Long Island helps people and their caregivers manage cancer care.
Cancer Prevention | NYU Langone Health
At NYU Langone’s Perlmutter Cancer Center, our cancer prevention programs provide steps to help avoid developing many types of cancer.
Cancer Rehabilitation | NYU Langone Health
At NYU Langone’s Rusk Rehabilitation, our oncology rehabilitation services can help improve physical function during cancer treatment.
Cancer Resources for Physicians | NYU Langone Health
We provide cancer resources for physicians and help doctors refer patients to NYU Langone’s Perlmutter Cancer Center.
Cancer Screening | NYU Langone Health
At NYU Langone’s Perlmutter Cancer Center, we offer screening for many types of cancer.
Cancer Support Services | NYU Langone Health
NYU Langone’s Perlmutter Cancer Center provides support services to improve wellbeing during and after cancer treatment.
Cancers, Tumors & Blood Disorders | NYU Langone Health
NYU Langone provides the highest quality care for children and adults with cancers, benign tumors, or blood disorders.
Cannabidiol for Treating PTSD symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid with TBI: A Placebo-controlled RCT with Neural-circuit centered Precision Medicine Prediction of Response.
This will be a randomized placebo controlled parallel dose finding study. The purpose of this project is to test the efficacy of cannabidiol (CBD) as a treatment for symptoms of post-traumatic stress disorder (PTSD) and neurocognitive impairment. Subjects, 120 in total, will be males and females with PTSD with, or without comorbid mild–moderate traumatic brain injury (TBI) (60 patients each group). We expect around half of all subjesct to be veterans. There will be three study arms: 1) 40 subjects assigned to oral CBD 400 mg daily; 2) 40 subjects assigned to CBD 800 mg daily, and 3) 40 subjects assigned to Placebo daily. Treatment duration will be 8 weeks. Randomization will be stratified on two variables: m–mTBI and veteran status. In order to generate a biomarker-informed precision medicine estimate of patient characteristics that predict treatment response, neuroimaging and blood-based biomarkers will be collected at baseline and following 8 weeks of treatment.